Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:PODD)’s stock, assigning a “Buy” rating with the price ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device ...